import Box from "@mui/material/Box"
import { Container } from "@mui/system"
import React from 'react'


export default function News() {
    return (
        <>
            <h1>
                News
            </h1>
            <Container>
                <Box>
                    <h3>
                        PLATFORM IMAGING, LLC. ANNOUNCES THE APPOINTMENT OF RAYMOND R. RACKLEY, M.D. TO THE MEDICAL ADVISORY BOARD
                    </h3>
                    <h5>
                        New York, NY, April 26, 2022
                    </h5>
                    <p>
                        Platform Imaging, a development stage, medical device company developing innovative, less invasive technologies for laparoscopic surgery, today announced that it has appointed Raymond R. Rackley, M.D. to the Medical Advisory Board.  While serving on the board, Dr. Rackley will oversee efforts and provide guidance in the development and commercialization of VisibotTM, an autonomous, disposable, miniaturized, fully insertable camera module for laparoscopic surgery to provide a less invasive technique for patients and surgeons, reduce OR time, reduce human resource requirement, reduce infection rate, eliminate reprocessing cost and risk, reduce or eliminate recurring long term capital expenditures and service fees, and facilitates opening of additional OR’s for laparoscopic procedures.
                    </p>

                    <p>
                        Steve Jones, CEO of Platform Imaging, commented, “We are fortunate to have Dr. Rackley join our Medical Advisory Board.  He will be i.       instrumental in helping us move the VisibotTM technology forward through design into commercialization.  His surgical as well as business leadership experience will be an outstanding asset to Platform.”
                    </p>

                    <p>
                        Raymond Rackley, MD, is Professor of Surgery at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and Staff in the Center for Pelvic Health and Reconstructive Surgery within the Glickman Urological and Kidney Institute. Dr. Rackley earned his biomedical engineering degree from Duke University and his medical degree from Case Western Reserve University. He completed a urology residency as well as fellowship training in voiding dysfunction and female urology at Cleveland Clinic. He currently holds Staff appointments in the Glickman Urological and Kidney Institute, the Department of Obstetrics and Gynecology, and the Lerner Research Institute as Director of the basic science Urothelial Biology Laboratory.
                    </p>

                    <p>
                        Dr. Rackley’s primary focus is on the clinical care of people with pelvic health disorders and the education of those who serve to improve pelvic health. In addition to his full-time clinical responsibilities, he actively manages an NIH and extramurally funded research laboratory for reconstructive and basic science investigations of the lower urinary tract.
                    </p>

                    <p>
                        During his leadership tenure within the Center of Pelvic Health and Reconstructive Surgery, the Center has evolved as one of the premier centers for national and international educational forums for residents, fellows and postgraduate physicians pursuing expansion of their basic science and clinical knowledge supporting their practices in pelvic health. Dr. Rackley’s programmatic developments for the Center includes formal preceptorships and CME courses held annually for urology residents, fellows, and postgraduate urologists, as well as guest preceptorships in clinical practice development and surgical training in pelvic health. He enjoys formal and informal didactic, as well as live, surgical telecast training forums of traditional and minimally invasive procedures such as laparoscopic approaches to pelvic reconstruction.
                    </p>

                    <p>
                        Dr. Rackley serves as the Principal Investigator and Co-Principal Investigator on NIH grants, as well as other extramural foundation and society grants that focus on bladder health and pelvic organ reconstructive developments. He has also authored or co-authored more than 100 peer-reviewed publications in clinical and basic science topics in pelvic health and urology including numerous chapters in the leading textbooks on urology and pelvic reconstructive surgery. He serves as a reviewer for the leading peer-reviewed national and international urology and gynecology journals, grant reviewer for foundations such as the National Kidney Foundation, and a committee member for the Data and Safety Monitoring Board for the NIH Clinical Research Trials Network for Interstitial Cystitis and Chronic Pelvic Pain and the Bladder Advisory Council of the AUA Foundation.
                    </p>

                    <p>
                        Laparoscopic Surgery
                    </p>
                    <p>
                        There are approximately 6 million laparoscopic procedures performed annually in the United States.  VisibotTM technology is applicable to approximately 80% of these.
                    </p>

                    <p>
                        Contact
                    </p>

                    <p>
                        Steve Jones, CEO, Platform Imaging, LLC.
                    </p>
                    <p>
                        sjones@platform-imaging.com
                    </p>
                </Box>

                <Box>
                    <h3>
                        PLATFORM IMAGING, LLC. ANNOUNCES NOTICE OF ALLOWANCE for a U.S. PATENT APPLICATION COVERING the IMPLANTATION, FIXATION and METHOD for VisibotTM
                    </h3>
                    <h5>
                        February 16, 2022
                    </h5>
                    <h4>
                        Forthcoming Issuance of a U.S. Patent Application Will Fortify and Broaden Platform Imaging’s Intellectual Property Portfolio Surrounding VisibotTM
                    </h4>

                    <p>

                        New York, NY, March 26, 2022—Platform Imaging, a development stage, medical device company developing innovative, less invasive technologies for laparoscopic surgery, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application (15/973,588) covering the device implantation, fixation, and method for VisibotTM, an autonomous, disposable, miniaturized, fully insertable camera module for laparoscopic surgery to provide a less invasive technique for patients and surgeons, reduce OR time, reduce human resource requirement, reduce infection rate, eliminate reprocessing cost and risk, reduce or eliminate recurring long term capital expenditures and service fees, and facilitates opening of additional OR’s for laparoscopic procedures.
                    </p>

                    <p>
                        “We are very pleased with this extension of our patent portfolio for VisibotTM.” Said Steve Jones, Chief Executive Officer of Platform Imaging. “This allowance expands the breadth and further validates our intellectual property coverage to allow Platform to develop and introduce innovative, less invasive technologies to surgeons and patients for laparoscopic surgery.”
                    </p>

                    <p>
                        Platform Imaging’s VisibotTM patent estate includes other granted U.S. and foreign patents and patent pending applications covering: Implantable Device and System for Minimal Access Procedures, Laparoscopic Device Implantation and Fixation System and Method, Insertable Surgical Imaging Device, Laparoscopic Surgical Device and Tool Tracking During Surgical Procedures.
                    </p>

                    <p>
                        Laparoscopic Surgery
                    </p>
                    <p>
                        There are approximately 6 million laparoscopic procedures performed annually in the United States.  VisibotTM technology is applicable to approximately 80% of these.
                    </p>

                    <p>
                        Contact
                    </p>

                    <p>
                        Steve Jones, CEO, Platform Imaging, LLC.
                    </p>

                    <p>
                        (239) 571-2828
                    </p>

                    <p>
                        sjones@platform-imaging.com
                    </p>


                </Box>

            </Container>
        </>

    )
}